Global Cell Viability Assays

Cell Viability Assays Comprehensive Study by Type (Human Cells, Microbial Cells, Animal Cells), Application (Basic Research, Stem Cell Research, Drug Discovery & Development, Clinical & Diagnostic Applications, Other), End-User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospital and Diagnostic Laboratories, Other) Players and Region - Global Market Outlook to 2028

Cell Viability Assays Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The proportion of live, healthy cells in a population is called cell viability. Cell viability assays are used to assess the overall health of cells, to improve culture or experimental conditions, and to assess cell survival after exposure to compounds, such as during a drug screen. The counting of a cell is done using viability dues, which can provide viable cell percentage and proliferation rate. In some cases, cell viability assays are performed on liver, cell, or tissue remains. In general, they search the cells for any unnatural reactions that they aren't supposed to have and scale them to determine viability. In all types of cell culture, cell viability is important. Cell viability assays provide the consumer with a different aspect of cell health and can be used to create an assay for determining cell viability or drug efficacy using several combined particles to provide a more accurate image. Due to the expanded use of cell viability assays for drug screening, cell viability assays are commonly used in both pharmaceutical trials and in vitro studies.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledThermo Fisher Scientific (United States), Bio-Rad Laboratories (United States), Merck Group (Germany), GE Healthcare (United States), BioTek Instruments(United States), PerkinElmer (United States), Promega Corporation(United States), Biotium(United States) and Abcam plc (United Kingdom)


This growth is primarily driven by Incidence and Prevalence of Chronic and Infectious Diseases are on the Rise and Rising Demand for Cell-based Assays in Research.

Globally, a noticeable market trend is evident Assays that use 3-D cell culture provide a tissue-like structure Major Players, such as Thermo Fisher Scientific (United States), Bio-Rad Laboratories (United States), Merck Group (Germany), GE Healthcare (United States), BioTek Instruments(United States), PerkinElmer (United States), Promega Corporation(United States), Biotium(United States) and Abcam plc (United Kingdom), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Key Developments in the Market:
In January 2023, GE HealthCare announced an agreement to acquire IMACTIS to strengthen its capabilities in interventional guidance. This acquisition is expected to provide significant future expansion opportunities.
April 2020 – BioTek Instruments introduced a new kit that can help researchers quickly obtain high-quality cell count results by automating the often tedious and error-prone process of mammalian cell counting.

Regulatory Insights:
The Food and Drug Administration (FDA) may require that cell viability assays used in drug development be validated and meet certain performance standards. The FDA may also require that the assay be included in the drug application as a part of the data package submitted for regulatory approval.

Influencing Trend:
Assays that use 3-D cell culture provide a tissue-like structure

Market Growth Drivers:
Incidence and Prevalence of Chronic and Infectious Diseases are on the Rise and Rising Demand for Cell-based Assays in Research

Challenges:
Lack of Professionals and Technical Experts to Run the Instruments

Restraints:
Stringent Government Regulations

Opportunities:
Growing Investments in R&D and Growth Opportunities in Untapped Markets

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Cell Viability Assays Market
- Analysis about New Entrants in Cell Viability Assays Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Cell Viability Assays Study Sheds Light on
— The Cell Viability Assays Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Cell Viability Assays industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Cell Viability Assays industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Human Cells
  • Microbial Cells
  • Animal Cells
By Application
  • Basic Research
  • Stem Cell Research
  • Drug Discovery & Development
  • Clinical & Diagnostic Applications
  • Other
By End-User
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Hospital and Diagnostic Laboratories
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Incidence and Prevalence of Chronic and Infectious Diseases are on the Rise
      • 3.2.2. Rising Demand for Cell-based Assays in Research
    • 3.3. Market Challenges
      • 3.3.1. Lack of Professionals and Technical Experts to Run the Instruments
    • 3.4. Market Trends
      • 3.4.1. Assays that use 3-D cell culture provide a tissue-like structure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cell Viability Assays, by Type, Application, End-User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cell Viability Assays (Value)
      • 5.2.1. Global Cell Viability Assays by: Type (Value)
        • 5.2.1.1. Human Cells
        • 5.2.1.2. Microbial Cells
        • 5.2.1.3. Animal Cells
      • 5.2.2. Global Cell Viability Assays by: Application (Value)
        • 5.2.2.1. Basic Research
        • 5.2.2.2. Stem Cell Research
        • 5.2.2.3. Drug Discovery & Development
        • 5.2.2.4. Clinical & Diagnostic Applications
        • 5.2.2.5. Other
      • 5.2.3. Global Cell Viability Assays by: End-User (Value)
        • 5.2.3.1. Academic and Research Institutes
        • 5.2.3.2. Pharmaceutical and Biotechnology Companies
        • 5.2.3.3. Hospital and Diagnostic Laboratories
        • 5.2.3.4. Other
      • 5.2.4. Global Cell Viability Assays Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Cell Viability Assays: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bio-Rad Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck Group (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GE Healthcare (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BioTek Instruments(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. PerkinElmer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Promega Corporation(United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biotium(United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abcam plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Cell Viability Assays Sale, by Type, Application, End-User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cell Viability Assays (Value)
      • 7.2.1. Global Cell Viability Assays by: Type (Value)
        • 7.2.1.1. Human Cells
        • 7.2.1.2. Microbial Cells
        • 7.2.1.3. Animal Cells
      • 7.2.2. Global Cell Viability Assays by: Application (Value)
        • 7.2.2.1. Basic Research
        • 7.2.2.2. Stem Cell Research
        • 7.2.2.3. Drug Discovery & Development
        • 7.2.2.4. Clinical & Diagnostic Applications
        • 7.2.2.5. Other
      • 7.2.3. Global Cell Viability Assays by: End-User (Value)
        • 7.2.3.1. Academic and Research Institutes
        • 7.2.3.2. Pharmaceutical and Biotechnology Companies
        • 7.2.3.3. Hospital and Diagnostic Laboratories
        • 7.2.3.4. Other
      • 7.2.4. Global Cell Viability Assays Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cell Viability Assays: by Type(USD Million)
  • Table 2. Cell Viability Assays Human Cells , by Region USD Million (2017-2022)
  • Table 3. Cell Viability Assays Microbial Cells , by Region USD Million (2017-2022)
  • Table 4. Cell Viability Assays Animal Cells , by Region USD Million (2017-2022)
  • Table 5. Cell Viability Assays: by Application(USD Million)
  • Table 6. Cell Viability Assays Basic Research , by Region USD Million (2017-2022)
  • Table 7. Cell Viability Assays Stem Cell Research , by Region USD Million (2017-2022)
  • Table 8. Cell Viability Assays Drug Discovery & Development , by Region USD Million (2017-2022)
  • Table 9. Cell Viability Assays Clinical & Diagnostic Applications , by Region USD Million (2017-2022)
  • Table 10. Cell Viability Assays Other , by Region USD Million (2017-2022)
  • Table 11. Cell Viability Assays: by End-User(USD Million)
  • Table 12. Cell Viability Assays Academic and Research Institutes , by Region USD Million (2017-2022)
  • Table 13. Cell Viability Assays Pharmaceutical and Biotechnology Companies , by Region USD Million (2017-2022)
  • Table 14. Cell Viability Assays Hospital and Diagnostic Laboratories , by Region USD Million (2017-2022)
  • Table 15. Cell Viability Assays Other , by Region USD Million (2017-2022)
  • Table 16. South America Cell Viability Assays, by Country USD Million (2017-2022)
  • Table 17. South America Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 18. South America Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 19. South America Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 20. Brazil Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 21. Brazil Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 22. Brazil Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 23. Argentina Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 24. Argentina Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 25. Argentina Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 26. Rest of South America Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 27. Rest of South America Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 28. Rest of South America Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 29. Asia Pacific Cell Viability Assays, by Country USD Million (2017-2022)
  • Table 30. Asia Pacific Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 31. Asia Pacific Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 32. Asia Pacific Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 33. China Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 34. China Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 35. China Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 36. Japan Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 37. Japan Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 38. Japan Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 39. India Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 40. India Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 41. India Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 42. South Korea Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 43. South Korea Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 44. South Korea Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 45. Taiwan Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 46. Taiwan Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 47. Taiwan Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 48. Australia Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 49. Australia Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 50. Australia Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 54. Europe Cell Viability Assays, by Country USD Million (2017-2022)
  • Table 55. Europe Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 56. Europe Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 57. Europe Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 58. Germany Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 59. Germany Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 60. Germany Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 61. France Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 62. France Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 63. France Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 64. Italy Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 65. Italy Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 66. Italy Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 67. United Kingdom Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 68. United Kingdom Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 69. United Kingdom Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 70. Netherlands Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 71. Netherlands Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 72. Netherlands Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 73. Rest of Europe Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 74. Rest of Europe Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 75. Rest of Europe Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 76. MEA Cell Viability Assays, by Country USD Million (2017-2022)
  • Table 77. MEA Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 78. MEA Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 79. MEA Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 80. Middle East Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 81. Middle East Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 82. Middle East Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 83. Africa Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 84. Africa Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 85. Africa Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 86. North America Cell Viability Assays, by Country USD Million (2017-2022)
  • Table 87. North America Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 88. North America Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 89. North America Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 90. United States Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 91. United States Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 92. United States Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 93. Canada Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 94. Canada Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 95. Canada Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 96. Mexico Cell Viability Assays, by Type USD Million (2017-2022)
  • Table 97. Mexico Cell Viability Assays, by Application USD Million (2017-2022)
  • Table 98. Mexico Cell Viability Assays, by End-User USD Million (2017-2022)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Cell Viability Assays: by Type(USD Million)
  • Table 109. Cell Viability Assays Human Cells , by Region USD Million (2023-2028)
  • Table 110. Cell Viability Assays Microbial Cells , by Region USD Million (2023-2028)
  • Table 111. Cell Viability Assays Animal Cells , by Region USD Million (2023-2028)
  • Table 112. Cell Viability Assays: by Application(USD Million)
  • Table 113. Cell Viability Assays Basic Research , by Region USD Million (2023-2028)
  • Table 114. Cell Viability Assays Stem Cell Research , by Region USD Million (2023-2028)
  • Table 115. Cell Viability Assays Drug Discovery & Development , by Region USD Million (2023-2028)
  • Table 116. Cell Viability Assays Clinical & Diagnostic Applications , by Region USD Million (2023-2028)
  • Table 117. Cell Viability Assays Other , by Region USD Million (2023-2028)
  • Table 118. Cell Viability Assays: by End-User(USD Million)
  • Table 119. Cell Viability Assays Academic and Research Institutes , by Region USD Million (2023-2028)
  • Table 120. Cell Viability Assays Pharmaceutical and Biotechnology Companies , by Region USD Million (2023-2028)
  • Table 121. Cell Viability Assays Hospital and Diagnostic Laboratories , by Region USD Million (2023-2028)
  • Table 122. Cell Viability Assays Other , by Region USD Million (2023-2028)
  • Table 123. South America Cell Viability Assays, by Country USD Million (2023-2028)
  • Table 124. South America Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 125. South America Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 126. South America Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 127. Brazil Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 128. Brazil Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 129. Brazil Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 130. Argentina Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 131. Argentina Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 132. Argentina Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 133. Rest of South America Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 134. Rest of South America Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 135. Rest of South America Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 136. Asia Pacific Cell Viability Assays, by Country USD Million (2023-2028)
  • Table 137. Asia Pacific Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 138. Asia Pacific Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 139. Asia Pacific Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 140. China Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 141. China Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 142. China Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 143. Japan Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 144. Japan Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 145. Japan Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 146. India Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 147. India Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 148. India Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 149. South Korea Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 150. South Korea Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 151. South Korea Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 152. Taiwan Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 153. Taiwan Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 154. Taiwan Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 155. Australia Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 156. Australia Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 157. Australia Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 158. Rest of Asia-Pacific Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 159. Rest of Asia-Pacific Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 160. Rest of Asia-Pacific Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 161. Europe Cell Viability Assays, by Country USD Million (2023-2028)
  • Table 162. Europe Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 163. Europe Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 164. Europe Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 165. Germany Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 166. Germany Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 167. Germany Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 168. France Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 169. France Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 170. France Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 171. Italy Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 172. Italy Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 173. Italy Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 174. United Kingdom Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 175. United Kingdom Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 176. United Kingdom Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 177. Netherlands Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 178. Netherlands Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 179. Netherlands Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 180. Rest of Europe Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 181. Rest of Europe Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 182. Rest of Europe Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 183. MEA Cell Viability Assays, by Country USD Million (2023-2028)
  • Table 184. MEA Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 185. MEA Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 186. MEA Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 187. Middle East Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 188. Middle East Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 189. Middle East Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 190. Africa Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 191. Africa Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 192. Africa Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 193. North America Cell Viability Assays, by Country USD Million (2023-2028)
  • Table 194. North America Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 195. North America Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 196. North America Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 197. United States Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 198. United States Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 199. United States Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 200. Canada Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 201. Canada Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 202. Canada Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 203. Mexico Cell Viability Assays, by Type USD Million (2023-2028)
  • Table 204. Mexico Cell Viability Assays, by Application USD Million (2023-2028)
  • Table 205. Mexico Cell Viability Assays, by End-User USD Million (2023-2028)
  • Table 206. Research Programs/Design for This Report
  • Table 207. Key Data Information from Secondary Sources
  • Table 208. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cell Viability Assays: by Type USD Million (2017-2022)
  • Figure 5. Global Cell Viability Assays: by Application USD Million (2017-2022)
  • Figure 6. Global Cell Viability Assays: by End-User USD Million (2017-2022)
  • Figure 7. South America Cell Viability Assays Share (%), by Country
  • Figure 8. Asia Pacific Cell Viability Assays Share (%), by Country
  • Figure 9. Europe Cell Viability Assays Share (%), by Country
  • Figure 10. MEA Cell Viability Assays Share (%), by Country
  • Figure 11. North America Cell Viability Assays Share (%), by Country
  • Figure 12. Global Cell Viability Assays share by Players 2022 (%)
  • Figure 13. Global Cell Viability Assays share by Players (Top 3) 2022(%)
  • Figure 14. Global Cell Viability Assays share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 17. Thermo Fisher Scientific (United States) Revenue: by Geography 2022
  • Figure 18. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bio-Rad Laboratories (United States) Revenue: by Geography 2022
  • Figure 20. Merck Group (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Merck Group (Germany) Revenue: by Geography 2022
  • Figure 22. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 23. GE Healthcare (United States) Revenue: by Geography 2022
  • Figure 24. BioTek Instruments(United States) Revenue, Net Income and Gross profit
  • Figure 25. BioTek Instruments(United States) Revenue: by Geography 2022
  • Figure 26. PerkinElmer (United States) Revenue, Net Income and Gross profit
  • Figure 27. PerkinElmer (United States) Revenue: by Geography 2022
  • Figure 28. Promega Corporation(United States) Revenue, Net Income and Gross profit
  • Figure 29. Promega Corporation(United States) Revenue: by Geography 2022
  • Figure 30. Biotium(United States) Revenue, Net Income and Gross profit
  • Figure 31. Biotium(United States) Revenue: by Geography 2022
  • Figure 32. Abcam plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Abcam plc (United Kingdom) Revenue: by Geography 2022
  • Figure 34. Global Cell Viability Assays: by Type USD Million (2023-2028)
  • Figure 35. Global Cell Viability Assays: by Application USD Million (2023-2028)
  • Figure 36. Global Cell Viability Assays: by End-User USD Million (2023-2028)
  • Figure 37. South America Cell Viability Assays Share (%), by Country
  • Figure 38. Asia Pacific Cell Viability Assays Share (%), by Country
  • Figure 39. Europe Cell Viability Assays Share (%), by Country
  • Figure 40. MEA Cell Viability Assays Share (%), by Country
  • Figure 41. North America Cell Viability Assays Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific (United States)
  • Bio-Rad Laboratories (United States)
  • Merck Group (Germany)
  • GE Healthcare (United States)
  • BioTek Instruments(United States)
  • PerkinElmer (United States)
  • Promega Corporation(United States)
  • Biotium(United States)
  • Abcam plc (United Kingdom)
Additional players considered in the study are as follows:
Biotium, Inc. (United States) , Canvax (Spain)
Select User Access Type

Key Highlights of Report


Jun 2023 233 Pages 55 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cell Viability Assays Quantitative research analysis
Global Cell Viability Assays Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Cell Viability Assays market are Thermo Fisher Scientific (United States), Bio-Rad Laboratories (United States), Merck Group (Germany), GE Healthcare (United States), BioTek Instruments(United States), PerkinElmer (United States), Promega Corporation(United States), Biotium(United States) and Abcam plc (United Kingdom), to name a few.
is dominating the Cell Viability Assays Market.
"Lack of Professionals and Technical Experts to Run the Instruments" is seen as one of the major challenges by many Industry Players of Cell Viability Assays Market
The Cell Viability Assays market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Cell Viability Assays market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Cell Viability Assays Report?

Have a Query? Click Here

Other Related Reports

Nutrigenomics Comprehensive Study by Type (Reagents & kits, Services), Application (Obesity, Diabetes, Anti-Aging, Chronic Diseases), Techniques (Saliva, Buccal Swab, Blood, Others) Players and Regio...
$ 3500
Genetically Modified Food Comprehensive Study by Type (Herbicide Tolerance (HR), Insect Resistance (IR), Stacked Traits (ST)), Application (Crops, Vegetables, Fruits, Animal Products), Crop (Corn, Co...
$ 3350
Plasmid DNA Manufacturing Comprehensive Study by Type (HQ Plasmid DNA, GMP Plasmid DNA, Non-GMP Plasmid DNA), Application (Cancer, Inherited Disorders, Viral Infections, DNA vaccines, DNA-based gene ...
$ 3750
Clinical Oncology Next Generation Sequencing (NGS) Comprehensive Study by Type (NGS Pre-Sequencing, Sequencing, NGS Data Analysis, Primary, Secondary & Tertiary Data Analysis), Application (Academic ...
$ 3750
Protein Crystallization Comprehensive Study by Application (Silico Drug Design, Binding Site Determination, Membrane Protein Structure Analysis, Others), Industry Verticals (Biotechnology, Pharmaceut...
$ 3750
Bioprocess Analyzers Comprehensive Study by Type (Substrate Analysis, Metabolite Analysis, Concentration Detection), Application (Antibiotics, Recombinant Proteins, Biosimilars, Others), Technology T...
$ 3650